SimpleScreen CRC
Freenome, LLC · Decision date Oct 27, 2026
What did the FDA decide?
The FDA record for P250029/S003 describes a 30-day notice supplement to PMA P250029 for SimpleScreen CRC, submitted by Freenome, LLC. The stated purpose is approval of supplier reagent manufacturing and Quality Control changes, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is listed as a system for colorectal neoplasia DNA methylation and hemoglobin detection.
The identifier establishes this as a supplement to an existing PMA, not an approval of the whole SimpleScreen CRC system. The source gives only the purpose statement for the supplier reagent manufacturing and quality control changes; it does not identify which reagent, supplier, or specific quality control parameters changed, nor does it provide data on safety or clinical performance. Those details are absent from the supplied record.
Regulatory and clinical conclusions beyond this descriptive paraphrase would go beyond the source. The notice's reported purpose should not be read as independent evidence of analytical validity, safety, or clinical effectiveness.
FDA approval order statement
approval of supplier reagent manufacturing and Quality Control changes.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Medical Genetics
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250029/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Freenome, LLC
- Product code
- PHP
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Freenome, LLC
- Product code
- PHP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250029 · Original PMA
SimpleScreen CRC
P250029/S003 received
Application receipt date recorded by FDA.
P250029/S003 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029 | Freenome, LLC | PMA approval | Jul 24, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
ShieldP230009 | Guardant Health, Inc. | PMA approval | Jul 26, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Freenome, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Bldg. 1, 3300 Marina Blvd., Brisbane, CA, 94005
Sources and methodology
- Original FDA record: P250029/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

